Beta Bionics, Inc. Common Stock (BBNX)vsEdwards Lifesciences Corp (EW)
BBNX
Beta Bionics, Inc. Common Stock
$15.17
-3.99%
HEALTHCARE · Cap: $785.18M
EW
Edwards Lifesciences Corp
$85.76
+2.49%
HEALTHCARE · Cap: $49.36B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 5618% more annual revenue ($6.30B vs $110.24M). EW leads profitability with a 17.4% profit margin vs -60.3%. EW earns a higher WallStSmart Score of 61/100 (C+).
BBNX
Hold36
out of 100
Grade: F
EW
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for BBNX.
Margin of Safety
+68.2%
Fair Value
$249.70
Current Price
$85.76
$163.94 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 56.6% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Strong operational efficiency at 31.2%
Safe zone — low bankruptcy risk
16.7% revenue growth
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -24.5% — below average capital efficiency
Negative free cash flow — burning cash
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : BBNX
The strongest argument for BBNX centers on Revenue Growth, Debt/Equity, Altman Z-Score. Revenue growth of 56.6% demonstrates continued momentum.
Bull Case : EW
The strongest argument for EW centers on Operating Margin, Altman Z-Score, Revenue Growth. Profitability is solid with margins at 17.4% and operating margin at 31.2%. Revenue growth of 16.7% demonstrates continued momentum.
Bear Case : BBNX
The primary concerns for BBNX are EPS Growth, Market Cap, Return on Equity.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 46.3x leaves little room for execution misses.
Key Dynamics to Monitor
BBNX profiles as a hypergrowth stock while EW is a growth play — different risk/reward profiles.
BBNX is growing revenue faster at 56.6% — sustainability is the question.
EW generates stronger free cash flow (-21M), providing more financial flexibility.
Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
EW scores higher overall (61/100 vs 36/100), backed by strong 17.4% margins and 16.7% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Beta Bionics, Inc. Common Stock
HEALTHCARE · MEDICAL DEVICES · USA
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. The company is headquartered in Irvine, California.
Visit Website →Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?